Development of a well-defined tool to predict the overall survival in lung cancer patients: an African based cohort-Reference-Cited by-全球学者库

Development of a well-defined tool to predict the overall survival in lung cancer patients: an African based cohort

Published:2023-10-20 Issue:1 Volume:23 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Tafenzi Hassan Abdelilah,Choulli Farah,Adjade Ganiou,Baladi Anas,Afani Leila,Fadli Mohammed El,Essaadi Ismail,Belbaraka Rhizlane

Abstract

Abstract Background Nomogram is a graphic representation containing the expressed factor of the mathematical formula used to define a particular phenomenon. We aim to build and internally validate a nomogram to predict overall survival (OS) in patients diagnosed with lung cancer (LC). Methods We included 1200 LC patients from a single institution registry diagnosed from 2013 to 2021. The independent prognostic factors of LC patients were identified via cox proportional hazard regression analysis. Based on the results of multivariate cox analysis, we constructed the nomogram to predict the OS of LC patients. Results We finally included a total of 1104 LC patients. Age, medical urgency at diagnosis, performance status, radiotherapy, and surgery were identified as prognostic factors, and integrated to build the nomogram. The model performance in predicting prognosis was measured by receiver operating characteristic curve. Calibration plots of 6-, 12-, and 24- months OS showed optimal agreement between observations and model predictions. Conclusion We have developed and validated a unique predictive tool that can offer patients with LC an individual OS prognosis. This useful prognostic model could aid doctors in making decisions and planning therapeutic trials.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

https://link.springer.com/content/pdf/10.1186/s12885-023-11355-7.pdf

Reference46 articles.

1. Zheng D, Wang Y, Li Y, Sun Y, Chen H. Predicting prognosis of post-chemotherapy patients with resected IIIA non-small cell lung cancer. J Thorac Dis. 2018;10(7):4186–94. Available from: http://jtd.amegroups.com/article/view/22525/17441. cited 2022 Nov 9.

2. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1556086415000179. cited 2022 Nov 9.

3. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer. J Thorac Oncol. 2009;4(7):792–801.

4. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC. J Thorac Oncol. 2010;5(5):620–30. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1556086415321353. cited 2022 Nov 9.

5. Mao A, Zhou X, Liu Y, Ding J, Miao A, Pan G. KLF8 is associated with poor prognosis and regulates glycolysis by targeting GLUT4 in gastric cancer. J Cell Mol Med. 2019;23(8):5087–97. Available from: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.14378. cited 2022 Nov 9.